Valencia, Feb. 2 (EFE). The Institute for Health Research (Incliva) is participating in a European project investigating novel biomarkers that would allow customized drug therapies for chronic kidney disease.
Leading experts from academic institutions, together with industry partners, the Dutch and European kidney institutions and the Dutch Board for Drug Evaluation are working on PRIME-CKD, an EU-funded project for clinical practice validation and implementation. Chronic kidney disease response to existing medications.
The PRIME-CKD (Personalized Response to Drugs: Implementation and Evaluation in Chronic Kidney Disease) project, which was launched in January and will last five years, will demonstrate in the clinical setting the usefulness of novel biomarkers as tools to improve drug selection. Treatments for patients, for use in both everyday clinical practice and innovative clinical trials.
This initiative, as Incliva mentioned in its statement, has brought together a large group of expert specialists in cardiovascular medicine, especially in chronic kidney disease, to address the main challenges that allow for the improvement of current treatments and the implementation of personalized medicine for the daily management of this disease.
Specifically, for the first time in a chronic disease context, the evaluation of biomarkers that link the pathophysiology of an individual disease to a drug’s mechanism of action will be sought – through the European Medicines Agency and the US Food and Drug Administration (FDA) – to advance personalized medicine, which will allow for adaptive therapies. With different responses for each patient.
“The results of this project are expected to translate into significant benefits for patients and reduced societal costs associated with chronic kidney disease, by ensuring that patients receive the most effective treatment in a timely manner to slow or prevent kidney failure requiring dialysis or transplantation,” says the program coordinator. Hiddo JL Heerspink of the University Medical Center Groningen, The Netherlands.
Participating in this project are the Enclaiva Health Research Institute’s Kidney Disease Research Team, led by Dr. Jose Luis Jurez.
His intervention is based on researching and analyzing biomarkers of patients with chronic kidney disease from the Department of Health of Valencia Clinico Malvarrosa in different phases of the project.
The findings will help reveal biomarkers of progression of kidney disease and different response to treatment and advanced personalized medicine adjusted to the characteristics and response of each patient.
Górriz expressed his satisfaction “to participate in the PRIME-CKD program, which is based on the solid line of kidney research and the vision of precision medicine that has been developed in Europe in recent years”.
“Without a doubt, it could be a huge step in preventing the progression of chronic kidney disease. There is still a lot to learn, especially regarding each patient’s individual response to current therapies. It is the future of kidney disease and cardiovascular medicine,” he added.
PRIME-CKD is funded by Horizon Europe, the European Union’s Horizon Europe research and innovation framework programme.
The total budget of the project is 9.9 million euros for a period of 5 years. In addition to Incliva, 14 other research centers are involved. EFE